Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$1.51B |
| 2 |
iShares US Real Estate ETF
IYR
|
+$985M |
| 3 |
Apple
AAPL
|
+$890M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$774M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$736M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$673M |
| 2 |
Bank of America
BAC
|
+$615M |
| 3 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$515M |
| 4 |
NVIDIA
NVDA
|
+$451M |
| 5 |
ATVI
Activision Blizzard
ATVI
|
+$417M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.95% |
| 2 | Financials | 8.18% |
| 3 | Consumer Discretionary | 7.81% |
| 4 | Healthcare | 7.12% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Caleres
CAL
$487M
| $2.9M | ﹤0.01% |
94,429
+15,943
| +20% | +$450K |
|
2552
AtriCure
ATRC
$2.11B
| $2.9M | ﹤0.01% |
81,295
+61,580
| +312% | +$2.29M |
|
|
OPLN
2553
Openlane
OPLN
$4.54B
| $2.89M | ﹤0.01% |
195,420
+142,198
| +267% | +$2.07M |
|
2554
CALL
BioMarin Pharmaceuticals
BMRN
$12.4B
| $2.89M | ﹤0.01% |
+30,000
| New | +$2.65M |
|
2555
Cameco
CCJ
$42.4B
| $2.89M | ﹤0.01% |
67,083
+22,840
| +52% | +$956K |
|
|
MDRX
2556
DELISTED
Veradigm Inc. Common Stock
MDRX
| $2.89M | ﹤0.01% |
275,542
+138,733
| +101% | +$1.7M |
|
2557
CALL
Albemarle
ALB
$15.5B
| $2.89M | ﹤0.01% |
+20,000
| New | +$2.75M |
|
2558
Edgewell Personal Care
EPC
$1.31B
| $2.89M | ﹤0.01% |
78,804
+54,059
| +218% | +$1.91M |
|
2559
Oxford Industries
OXM
$552M
| $2.89M | ﹤0.01% |
28,865
+17,523
| +154% | +$1.63M |
|
2560
Kemper
KMPR
$1.68B
| $2.88M | ﹤0.01% |
59,272
+27,103
| +84% | +$1.19M |
|
2561
Goosehead Insurance
GSHD
$2.32B
| $2.88M | ﹤0.01% |
38,050
-153,351
| -80% | -$11.1M |
|
2562
StepStone Group
STEP
$3.82B
| $2.88M | ﹤0.01% |
90,452
+66,383
| +276% | +$1.88M |
|
2563
Construction Partners
ROAD
$6.77B
| $2.88M | ﹤0.01% |
66,132
+50,831
| +332% | +$2.08M |
|
2564
Shift4
FOUR
$3.26B
| $2.88M | ﹤0.01% |
38,682
+22,888
| +145% | +$1.37M |
|
2565
Pacira BioSciences
PCRX
$997M
| $2.87M | ﹤0.01% |
85,049
+51,645
| +155% | +$1.51M |
|
2566
Scotiabank
BNS
$108B
| $2.87M | ﹤0.01% |
58,912
+35,236
| +149% | +$1.55M |
|
2567
VanEck Oil Services ETF
OIH
$1.84B
| $2.87M | ﹤0.01% |
9,264
-1
| -0% | -$321 |
|
2568
Integra LifeSciences
IART
$1.34B
| $2.87M | ﹤0.01% |
65,805
+24,327
| +59% | +$957K |
|
2569
PUT
Travelers Companies
TRV
$80.2B
| $2.86M | ﹤0.01% |
15,000
-47,600
| -76% | -$8.24M |
|
2570
Doximity
DOCS
$4.88B
| $2.85M | ﹤0.01% |
101,779
-92,903
| -48% | -$2.19M |
|
|
RDFN
2571
DELISTED
Redfin
RDFN
| $2.85M | ﹤0.01% |
276,154
+222,953
| +419% | +$1.55M |
|
|
RPC
2572
Ridgepost Capital
RPC
$991M
| $2.85M | ﹤0.01% |
278,643
+152,181
| +120% | +$1.5M |
|
|
AMAM
2573
DELISTED
Ambrx Biopharma Inc
AMAM
| $2.85M | ﹤0.01% |
+199,950
| New | +$2.27M |
|
2574
CALL
Tilray
TLRY
$622M
| $2.84M | ﹤0.01% |
+123,500
| New | +$2.38M |
|
2575
PUT
Yelp
YELP
$1.41B
| $2.84M | ﹤0.01% |
+60,000
| New | +$2.65M |
|
Similar funds
Barclays's Q4 2023 Portfolio in Review
As of Q4 2023, Barclays held 5,469 positions worth $273B, up 70% from $161B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Barclays deployed $85.1B of net new capital in Q4 2023, opening 898 new positions and adding to 2,915 existing holdings. Its largest new stake was AngloGold Ashanti: 9,667,894 shares worth $181M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 27% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $673M trimmed.
- Barclays's largest Q4 2023 buy was AngloGold Ashanti: 9,667,894 shares worth $181M.
- Barclays added most to Meta Platforms (Facebook) in Q4 2023, an estimated $1.51B increase.
- Barclays's biggest Q4 2023 reduction was CRH, cutting an estimated $673M.
- Barclays fully exited Activision Blizzard in Q4 2023, selling an estimated $417M.
- Barclays's ten largest holdings make up 27% of its $273B portfolio in Q4 2023.
- Barclays opened 898 new positions and closed 253 in Q4 2023.
- Barclays's portfolio value rose 70% quarter-over-quarter to $273B.
Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.